A vaccine for the terminal HIV Aids infection could be a reality within the next decade, thanks to a research being conducted by Johnson and Johnson. Researchers from various countries have been working on an HIV vaccine for the last few decades but success has been elusive. But in July this year, the first clinical trial of an early stage vaccine took place and the results were encouraging.
Johnson and Johnson vice president Hanneke Schuitemaker confirmed that it took 12 to 13 years to get the vaccine to this stage. Application of the vaccine on healthy humans resulted in immune response within accepted levels of tolerance. He also mentioned that the trials conducted in the field of Ebola vaccine development helped in HIV vaccination research as well. It will require many trials and much more research before a working HIV vaccine becomes available but the hope is pretty much there.